Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that CEO Steve Hoerter will present at two upcoming investor conferences: the Guggenheim 2022 Oncology Virtual Conference on February 9, 2022, at 8:30 AM ET and the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 3:40 PM ET. Live webcasts of both events will be available on the company's website, with replays accessible for 90 days post-presentation. Deciphera focuses on developing innovative cancer treatments, including its approved QINLOCK® for fourth-line GIST in various regions, including the U.S.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the following investor conferences:

• Guggenheim 2022 Oncology Virtual Conference on February 9, 2022 at 8:30 AM ET
• 11^th Annual SVB Leerink Global Healthcare Conference on February 16, 2022 at 3:40 PM ET

A live webcast of both events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of both webcasts will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK^® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220202005016/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902

Media:

David Rosen

Argot Partners

David.Rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

What are the dates of the investor conferences for Deciphera Pharmaceuticals (DCPH)?

Deciphera Pharmaceuticals (DCPH) will present at two investor conferences: Guggenheim 2022 Oncology Virtual Conference on February 9, 2022, and the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022.

What time will Deciphera Pharmaceuticals present at the Guggenheim Conference?

Deciphera Pharmaceuticals will present at the Guggenheim 2022 Oncology Virtual Conference on February 9, 2022, at 8:30 AM ET.

Where can I watch the Deciphera Pharmaceuticals (DCPH) conference presentations?

The live webcasts of Deciphera Pharmaceuticals' conference presentations can be found on the 'Events and Presentations' page in the 'Investors' section of their website.

How long will the webcasts of Deciphera Pharmaceuticals' presentations be available?

The replays of Deciphera Pharmaceuticals' conference webcasts will be archived on their website for 90 days following the presentations.

What is QINLOCK® and its significance for Deciphera Pharmaceuticals?

QINLOCK® is a switch-control kinase inhibitor developed by Deciphera Pharmaceuticals for the treatment of fourth-line GIST, currently approved in multiple regions, including the U.S.